Search

Without access to treatment, can we truly innovate in rare diseases?

Interview with Giampaolo Merlini

There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.

Read more

Community and Stakeholder Committee

Current committee members
Gianluca Gaidano, Italy (Chair)
Helen Papadaki, Greece (Chair)
Donal McLornan, United Kingdom (Vice-Chair)
Meritxell Alberich Jordà, Czech Republic (Councilor)
Arndt Borkhardt, Germany (Research Committee representative)
Raul Córdoba Mascuñano, Spain (Councilor)
Margarita Guenova, Bulgaria (Councilor)
Mandy Lauw, The Netherlands (YoungEHA representative)
Ivo Touw, The Netherlands (Education Committee…

Read more

EHA-MSH Hematology Tutorial

EHA is joining forces with the Malaysian Society of Haematology (MSH) to organize the EHA-MSH Hematology Tutorial on Hodgkin Lymphoma.

Read more

EHA Research Grants

The call for applications will close on October 15, 2024, at 15:00 (CEST).

Read more

Other Useful Resources

Latest EMA publications on COVID-19 vaccines
COVID-19 Vaccine Janssen: update on safety issues
First COVID-19 vaccine approved for children aged 12 to 15 in EU
Insufficient data on use of inhaled corticosteroids to treat COVID-19
EMA issues advice on use of sotrovimab (VIR-7831) for…

Read more

EU pilot on drug repurposing

Drug repurposing (finding new indications for existing authorized medicines) is increasingly prominent in the debate about improving access to medicines. As stated in EHA’s position paper on access to affordable orphan medicines (Merlini et al.

Read more

EHA policy on double awarding

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed. Winning an award excludes the award winner from winning another award while receiving the first.

Read more

EHA policy on double awarding

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed.

Read more